


APPENDIX B
PENDING CLAIMS 1-17 and 19-32

1. (Amended) A compound selected from the group of compounds represented by Formula (I):



wherein:

R¹ is hydrogen or acyl;

R² is hydrogen or alkyl;

A and B are simultaneously an aryl or a heteroaryl ring;

R³ is selected from the group consisting of:

- (c) optionally substituted heterocyclyl;
- (d) optionally substituted aryl or heteroaryl;
- (e) heteroalkyl substituted with a heteroaryl or heterocyclyl group;
- (f) heteroalkenyl;
- (g) heteroalkynyl;
- (i) heteroalkylamino;
- (j) optionally substituted heterocyclylalkyl;
- (k) optionally substituted heterocyclylalkenyl;
- (l) optionally substituted heterocyclylalkynyl;
- (m) optionally substituted heterocyclylalkoxy, cycloxy or heterocycloxy;
- (n) optionally substituted heterocyclylalkylamino;
- (o) optionally substituted heterocyclylalkylcarbonyl;

- (p) heteroalkylcarbonyl;
- (s) $-Y-(\text{alkylene})-R^9$ where:
 Y is a single bond, $-O-$, $-NH-$ or $-S(O)_n-$ (where n is an integer from 0 to 2); and
 R^9 is cyano, optionally substituted heteroaryl, $-COOH$, $-COR^{10}$, $-COOR^{11}$, $-CONR^{12}R^{13}$, $-SO_2R^{14}$, $-SO_2NR^{15}R^{16}$, $-NHSO_2R^{17}$ or $-NHSO_2NR^{18}R^{19}$, where R^{10} is alkyl or optionally substituted heterocycle, R^{11} is alkyl, and R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} and R^{19} are, independently of each other, hydrogen, alkyl or heteroalkyl;
- (t) $-C(=NR^{20})(NR^{21}R^{22})$ where R^{20} , R^{21} and R^{22} independently represent hydrogen, alkyl or hydroxy, or R^{20} and R^{21} together are $-(CH_2)_n-$ where n is 2 or 3 and R^{22} is hydrogen or alkyl;
- (u) $-NHC(X)NR^{23}R^{24}$ where X is $-O-$ or $-S-$, and R^{23} and R^{24} are, independently of each other, hydrogen, alkyl or heteroalkyl;
- (v) $-CONR^{25}R^{26}$ where R^{25} and R^{26} independently represent hydrogen, alkyl, heteroalkyl or optionally substituted heterocyclalkyl, or R^{25} and R^{26} together with the nitrogen to which they are attached form an optionally substituted heterocycl ring;
- (x) cycloalkylalkyl, cycloalkylalkynyl and cycloalkylalkynyl, all optionally substituted with alkyl, halo, hydroxy or amino;
- (y) arylaminoalkylene or heteroarylaminoalkylene;
- (z) $Z\text{-alkylene-NR}^{30}R^{31}$ or $Z\text{-alkylene-OR}^{32}$ where Z is $-NH-$, $-N(\text{lower alkyl})-$ or $-O-$, and R^{30} , R^{31} and R^{32} are independently of each other, hydrogen, alkyl or heteroalkyl;
- (aa) $-OC(O)\text{-alkylene-CO}_2H$ or $-OC(O)\text{-NR}'R''$ (where R' and R'' are independently hydrogen or alkyl); and
- (bb) heteroarylalkenylene or heteroarylalkynylene;

R⁴ is selected from the group consisting of:

- (a) hydrogen;
- (b) halo;
- (c) alkyl;
- (d) alkoxy; and
- (e) hydroxy;

R⁵ is selected from the group consisting of :

- (a) hydrogen;
- (b) halo;
- (c) alkyl;
- (d) haloalkyl;
- (e) thioalkyl;
- (f) hydroxy;
- (g) amino;
- (h) alkylamino;
- (i) dialkylamino;
- (j) heteroalkyl;
- (k) optionally substituted heterocycle;
- (l) optionally substituted heterocyclalkyl;
- (m) optionally substituted heterocyclalkoxy;
- (n) alkylsulfonyl;
- (o) aminosulfonyl, mono-alkylaminosulfonyl or di-alkylaminosulfonyl;
- (p) heteroalkoxy; and
- (q) carboxy;

R⁶ is selected from the group consisting of:

- (a) hydrogen;
- (b) halo;
- (c) alkyl; and
- (d) alkoxy; and

prodrugs, individual isomers, mixtures of isomers and pharmaceutically acceptable salts thereof.

2. (Amended) The compound of Claim 1 wherein R^3 is:
 - (a) optionally substituted heterocyclyl;
 - (b) aryl or heteroaryl both optionally substituted with a substituent selected from halo, alkyl, amino, alkoxy, carboxy, lower alkoxy carbonyl, SO_2R' (where R' is alkyl) or $SO_2NHR'R''$ (where R' and R'' are independently hydrogen or alkyl);
 - (c) heteroalkyl substituted with a heteroaryl or a heterocyclyl group;
 - (d) heteroalkenyl;
 - (e) heteroalkylamino;
 - (g) optionally substituted heterocyclylalkyl or heterocyclyoxy;
 - (h) optionally substituted heterocyclylalkenyl;
 - (i) optionally substituted heterocyclylalkynyl;
 - (j) optionally substituted heterocyclylalkoxy;
 - (k) optionally substituted heterocyclylalkylamino;
 - (l) optionally substituted heterocyclylalkylcarbonyl;
 - (k) $-Y-(alkylene)-R^9$ where Y is a single bond, $-O-$ or $-NH-$ and R^9 is optionally substituted heteroaryl, $-CONR^{12}R^{13}$, SO_2R^{14} , $-SO_2NR^{15}R^{16}$, $-NHSO_2R^{17}$ or $-NHSO_2NR^{18}R^{19}$ where R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} and R^{19} are independently of each other hydrogen, alkyl or heteroalkyl;
 - (l) cycloalkylalkyl, cycloalkylalkynyl and cycloalkylalkynyl, all optionally substituted with alkyl, halo, hydroxy or amino;
 - (m) arylaminoalkylene or heteroarylaminoalkylene; or
 - (n) $Z-alkylene-NR^{30}R^{31}$ where Z is $-NH-$, $-N(alkyl)-$ or $-O-$, and R^{30} and R^{31} are independently of each other, hydrogen, alkyl or heteroalkyl.
3. The compound of Claim 2 wherein R^1 and R^2 are hydrogen; and B is phenyl.

4. The compound of Claim 3 wherein A is phenyl.
5. The compound of Claim 4 wherein R⁴ is hydrogen; and R⁵ is halo or alkyl.
6. The compound of Claim 5 wherein R⁵ is chloro, fluoro or methyl; and R⁶ is hydrogen, chloro, fluoro, methyl or methoxy.
7. The compound of Claim 5, wherein R³ is optionally substituted heteroaryl.
8. The compound of Claim 7, wherein R³ is pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, N-oxidopyridin-2-yl, N-oxidopyridin-3-yl, N-oxidopyridin-4-yl or pyridon-2-yl, all optionally substituted.
9. The compound of Claim 8, wherein R³ is at the 3-position.
10. The compound of Claim 9, wherein R⁵ is 4-F and R⁶ is hydrogen.
11. The compound of Claim 9, wherein R⁵ is 2-Me and R⁶ is hydrogen.
12. The compound of Claim 5, wherein R³ is optionally substituted phenyl.
13. The compound of Claim 12, wherein R³ is 3-sulfamoylphenyl, 3-methylsulfonylphenyl, 3-carboxyphenyl or 3-ethoxycarbonylphenyl.
14. The compound of Claim 13, wherein R³ is at the 3-position.
15. The compound of Claim 14, wherein R⁵ is 4-F and R⁶ is hydrogen.

16. (Amended) The compound of Claim 5, wherein R^3 is:
- (a) heteroalkyl substituted with a heteroaryl or a heterocyclyl group;
 - (b) heteroalkoxy;
 - (c) heteroalkylamino;
 - (d) optionally substituted heterocyclylalkyl;
 - (e) optionally substituted heterocyclylalkoxy;
 - (f) optionally substituted heterocyclylalkylamino;
 - (g) $-Y-(alkylene)-R^9$ where Y is a single bond, $-O-$ or $-NH-$ and R^9 is optionally substituted heteroaryl, $-CONR^{12}R^{13}$, SO_2R^{14} , $-SO_2NR^{15}R^{16}$, $-NHSO_2R^{17}$ or $-NHSO_2NR^{18}R^{19}$ where R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} and R^{19} are independently of each other hydrogen, alkyl or heteroalkyl; or
 - (h) $Z-alkylene-NR^{30}R^{31}$ where Z is $-NH-$, $-N(alkyl)-$ or $-O-$, and R^{30} and R^{31} are independently of each other, hydrogen, alkyl or heteroalkyl.
17. (Amended) The compound of Claim 16, wherein R^3 is heteroalkyl substituted with a heteroaryl or a heterocyclyl group.
19. The compound of Claim 18, wherein R^5 is 2-F and R^6 is 4-F.
20. The compound of Claim 18, wherein R^5 is 4-F and R^6 is hydrogen.
21. The compound of Claim 18, wherein R^5 is 2-Me and R^6 is hydrogen.
22. The compound of Claim 16, wherein R^3 is heteroalkoxy or heteroalkylamino.
23. The compound of Claim 22, wherein R^3 is at the 3-position and is selected from the group consisting of 3-dimethylaminopropoxy, 2-dimethylaminoethoxy, 2-hydroxyethoxy, 2,3-dihydroxypropoxy, 2-dimethylaminoethylamino and 3-dimethylaminopropylamino.
24. The compound of Claim 23 wherein R^5 is 4-F or 2-Me and R^6 is hydrogen.

25. The compound of Claim 16, wherein R^3 is optionally substituted heterocyclalkyl, optionally substituted heterocyclalkoxy or optionally substituted heterocyclalkylamino.
26. The compound of Claim 25, wherein R^3 is at the 3-position and is selected from the group consisting of 3-(morpholin-4-yl)propoxy, 2-(morpholin-4-yl)ethoxy, 2-(2-oxo-pyrrolidin-1-yl)ethoxy, 3-(morpholin-4-yl)propyl, 2-(morpholin-4-yl)ethyl, 4-(morpholin-4-yl)butyl, 3-(morpholin-4-yl)propylamino, 2-(morpholin-4-yl)ethylamino, 4-hydroxypiperidinylmethyl, 2-(S,S-dioxo-thiamorpholin-4-yl)ethyl, 3-(S,S-dioxo-thiamorpholin-4-yl)propyl and N-methylpiperazinylmethyl.
27. The compound of Claim 26 wherein R^5 is 4-F or 2-Me and R^6 is hydrogen.
28. The compound of Claim 16 wherein R^3 is -Y-(alkylene)- R^9 where Y is a single bond, -O- or -NH- and R^9 is optionally substituted heteroaryl, -CONR¹²R¹³, SO₂R¹⁴, -SO₂NR¹⁵R¹⁶, -NHSO₂R¹⁷ or -NHSO₂NR¹⁸R¹⁹ where R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ are independently of each other hydrogen, alkyl or heteroalkyl.
29. The compound of Claim 28, wherein Y is a single bond and R^9 is SO₂R¹⁴ or -SO₂NR¹⁵R¹⁶.
30. The compound of Claim 29 wherein R^3 is methylsulfonyl ethyl or sulfamoyl ethyl.
31. The compound of Claim 30 wherein R^5 is 4-F or 2-Me and R^6 is hydrogen.
32. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable excipient.

* * * * *